Keyphrases
Group 3 Medulloblastoma
100%
Histone Deacetylase 2 (HDAC2)
100%
Histone Deacetylase Inhibitor (HDACi)
83%
Medulloblastoma
50%
Medulloblastoma Subgroups
33%
Metabolic Activity
33%
Class I HDACs
33%
Class IIa HDACs
33%
Binding Kinetics
33%
Tumor
16%
Epigenetics
16%
Clinical Trials
16%
Drug Target
16%
Cell Viability
16%
Childhood Brain Tumors
16%
Molecular Mechanism
16%
Clinical Characteristics
16%
Genetic Characteristics
16%
Protein Expression
16%
Cell number
16%
Poor Prognosis
16%
Cell Cycle Progression
16%
Dosing Regimen
16%
Clinical Pharmacology
16%
Cell Cycle Proteins
16%
Primary Brain Tumor
16%
Normal Brain Tissues
16%
Normal Brain
16%
Induced Cell Death
16%
Caspase Activity
16%
Enzymatic Activity
16%
Cellular Viability
16%
RNA Expression
16%
MYC Amplification
16%
Inhibitor Compound
16%
Histone Deacetylase Activity
16%
Translational Implications
16%
H4 Acetylation
16%
Inhibitory Profile
16%
Target Behavior
16%
Immunology and Microbiology
Binding Kinetics
100%
Protein Expression
50%
Cell Count
50%
Cell Death
50%
Cell Cycle Progression
50%
Cell Viability
50%
Epigenetics
50%
Cell Line
50%
Medulloblastoma Cell Line
50%
Cell Activity
50%
Brain Tissue
50%
Caspase
50%
Pharmacokinetics
50%
Acetylation
50%
Enzyme Activity
50%
Medicine and Dentistry
Medulloblastoma
100%
Histone Deacetylase 2
100%
Histone Deacetylase Inhibitor
66%
Histone Deacetylase
33%
Binding Kinetics
33%
Neoplasm
16%
Clinical Trial
16%
Cell Viability
16%
Cell Line
16%
Protein Expression
16%
Cell Death
16%
Brain Tissue
16%
Cell Cycle Progression
16%
Brain Cancer
16%
Cell Activity
16%
Acetylation
16%
Pharmacokinetics
16%
Caspase
16%
Medulloblastoma Cell Line
16%
Cell Cycle Protein
16%
Enzyme Activity
16%
Neuroscience
Medulloblastoma
100%
Histone Deacetylase 2
100%
Histone Deacetylase Inhibitor
66%
Cell Line
33%
Binding Kinetics
33%
Histone Deacetylase
33%
Cell Viability
16%
Brain Tumor
16%
Protein Expression
16%
Cell Cycle Protein
16%
Cell Cycle Progression
16%
Cell Activity
16%
Enzyme Activity
16%
Acetylation
16%
Cell Death
16%
Caspase
16%
Pharmacokinetics
16%
Biochemistry, Genetics and Molecular Biology
Histone Deacetylase 2
100%
Histone Deacetylase
50%
Binding Kinetics
33%
Clinical Trial
16%
Cell Viability
16%
Genetics
16%
Protein Expression
16%
Cell Death
16%
Cell Cycle Progression
16%
Acetylation
16%
RNA
16%
Epigenetics
16%
Cell Activity
16%
Caspase
16%
Pharmacokinetics
16%
Cell Count
16%
Enzyme Activity
16%
Pharmacology, Toxicology and Pharmaceutical Science
Medulloblastoma
100%
Histone Deacetylase 2
100%
Histone Deacetylase Inhibitor
66%
Histone Deacetylase
33%
Clinical Trial
16%
Neoplasm
16%
Brain Cancer
16%
Clinical Pharmacokinetics
16%
Caspase
16%
Target Activity
16%